<DOC>
	<DOC>NCT00392587</DOC>
	<brief_summary>The purpose of this study is to assess the safety of GW856553 in COPD patients and to assess its affects on their COPD disease after 14 days.</brief_summary>
	<brief_title>A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criteria: Women of childbearing potential Established history of COPD Cigarette smoking history greater than 10 pack years FEV1 between 40 and 80% of predicted normal for height, age and sex. Exclusion criteria: Morbidly obese patients (body mass index &gt;40) Hospitalisation or treatment for worsening of COPD in past 6 weeks History of increased liver function tests hypersensitivity to salbutamol or ipratropium bromide Blood pressure &gt; 155/95</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tolerability</keyword>
	<keyword>COPD</keyword>
	<keyword>Safety</keyword>
</DOC>